{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"The MTD is the highest dose at which ≤1 of 6 patients experienced a dose limiting toxicity (DLT) or the highest dose level studied if DLTs are not observed at any of the dose levels.","groups":[{"description":"All treated subjects who received at least one dose of human papilloma virus (HPV)-16 E6 monoclonal T cell receptor (mTCR) peripheral blood lymphocytes (PBL) 1x10\\^9, 1x10\\^10,1x10\\^11, \\>1x10\\^11 up to 2x10\\^11 + high-dose (HD) interleukin 2 (IL-2) were included.","id":"OG000","title":"All Treated Subjects"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"participants were followed for the duration of hospital stay, an average of 3 weeks","title":"Maximum Tolerated Dose (MTD)","type":"PRIMARY","unitOfMeasure":"# of cells x 10^11"}